MedPath

Study for the effect of Danlou tablet on gut microbiota of CHD patients and its metabolomics

Phase 4
Not yet recruiting
Conditions
coronary heart disease
Registration Number
ITMCTR1900002563
Lead Sponsor
Traditional Chinese Medicine Hospital of Tailai County, Qiqihar City, Heilongjiang Province
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Aged between 40-85 years;
2. Meets the diagnostic criteria for stable coronary heart disease;
3. singed the consent form.

Exclusion Criteria

1. Combined with Congenital heart disease, rheumatic heart disease, unstable angina pectoris;
2. Combined with Valvular disease, suspected major artery dissection, arrhythmia, acute heart failure, moderate to severe pulmonary hypertension, acute pulmonary embolism and other serious cardiopulmonary dysfunction;
3. Combined with Severe liver and kidney dysfunction, immune diseases;
4. Combined with acute infection;
5. Patients who used antibiotics, other lipid-lowering and blood-glucose lowering drugs and other Chinese medicines before 2 weeks and during the experiment;
6. Involuntary patients, poor compliance;
7. Participated in other clinical trials.

Study & Design

Study Type
Basic Science
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.